Skip to main content
DisclosureSome pages on this site contain affiliate links; we may earn a commission when you buy through them. Our scores and rankings follow our published methodology; commissions do not influence them. Read our methodology →
CholinergicClinical dose · 100–300mg/day (benefit shown mainly in older adults with memory complaints or MCI)Onset · Memory trials ran 15 weeks to 12 months; no trial established an earlier onset

Phosphatidylserine

RCTs in older adults with memory complaints or mild cognitive impairment report memory benefits, though often only in subgroups: soy PS at 100–300mg/day for 6 months helped only participants with low baseline scores (Kato-Kataoka 2010), and marine PS-DHA at 300mg/day improved immediate verbal recall in an exploratory 15-week trial (Vakhapova 2010). A 2026 network meta-analysis in MCI/Alzheimer's found PS 100mg improved MMSE but not the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog). In healthy children, a 12-week RCT of 100mg sunflower PS found no effect on primary or secondary outcomes (Friling 2025; authors include staff of IFF, the product's manufacturer). A positive 2024 MCI trial (Duan 2024; BYHEALTH co-authors) gave only 31.5mg PS inside a multi-ingredient formula. The FDA allows only a qualified claim that it may reduce the risk of dementia or cognitive dysfunction in the elderly, with the disclaimer that 'FDA concludes that there is little scientific evidence supporting this claim' (FDA letter, 13 May 2003).

By The Nootropic Lab editorial teamUpdated 8 min read✓ Fact-checked

Evidence reviewed:

Mechanism of action

Phosphatidylserine (PS) is a phospholipid that forms a critical component of neuronal cell membranes. It supports signal transduction across synapses, facilitates acetylcholine and dopamine release, and modulates cortisol secretion. Supplementation replenishes PS levels that decline naturally with age.

Clinical evidence summary

RCTs in older adults with memory complaints or mild cognitive impairment report memory benefits, though often only in subgroups: soy PS at 100–300mg/day for 6 months helped only participants with low baseline scores (Kato-Kataoka 2010), and marine PS-DHA at 300mg/day improved immediate verbal recall in an exploratory 15-week trial (Vakhapova 2010). A 2026 network meta-analysis in MCI/Alzheimer's found PS 100mg improved MMSE but not the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog). In healthy children, a 12-week RCT of 100mg sunflower PS found no effect on primary or secondary outcomes (Friling 2025; authors include staff of IFF, the product's manufacturer). A positive 2024 MCI trial (Duan 2024; BYHEALTH co-authors) gave only 31.5mg PS inside a multi-ingredient formula. The FDA allows only a qualified claim that it may reduce the risk of dementia or cognitive dysfunction in the elderly, with the disclaimer that 'FDA concludes that there is little scientific evidence supporting this claim' (FDA letter, 13 May 2003).

Human effect matrix

Based on human clinical trials only. Animal and in-vitro data excluded.

EffectEvidenceMagnitudeStudies
Memory Recall strong
Moderate
4
Cortisol Reduction moderate
Moderate
—
Processing Speed moderate
Small
—
Age-Related Cognitive Decline moderate
Small
1

Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results

Documented benefits

  • Memory recall in older adults with memory complaints (often subgroup-only)
  • MMSE scores in MCI/Alzheimer's (network meta-analysis)
  • Cortisol reduction under stress (not re-verified in our 2026 review)

Side effects & cautions

  • Well tolerated — no safety differences versus placebo over 15 weeks at 300mg/day
  • Mild GI discomfort in some users
  • Open-label 100mg/day extension: small drop in resting diastolic blood pressure and slight weight gain

How to take

Dosage100–300mg/day — benefit is most consistent in older adults and MCI, and in subgroup analyses; a 100mg/day trial in healthy children was null
TimingWith meals — split doses across 2–3 meals for best results (e.g. 100mg with breakfast, 100mg with lunch)
With foodPS is a fat-soluble phospholipid and absorbs best with dietary fat. Always take with food. Splitting doses across meals is better than a single large dose.
FormsCapsule (softgel preferred). There are three source types: (1) Soy-derived — most common, cheapest, effective but contains soy; (2) Sunflower-derived — soy-free, preferred option; (3) Bovine-brain-derived — used in original 1990s trials, no longer commercially available due to BSE concerns. Sharp-PS from sunflower is the benchmark form.

Stacking recommendations

Ingredients that pair well with Phosphatidylserine and why.

PS maintains cell membrane integrity while Lion's Mane drives NGF synthesis. Both support long-term brain health via complementary structural and growth-factor pathways.

Both are membrane phospholipid precursors, but they work on different pathways. Citicoline primarily builds phosphatidylcholine; PS addresses phosphatidylserine. Together they provide comprehensive neuronal membrane support.

DHA is a structural component of neuronal membranes. Some clinical PS products are DHA-conjugated (PS-DHA): a 15-week trial of marine PS-DHA at 300mg/day improved immediate verbal recall in older adults with memory complaints.

Frequently asked questions

Soy-derived vs sunflower PS — which is better?

Both are used in trials: soy PS in older adults with memory complaints (Kato-Kataoka 2010) and sunflower PS in healthy children, where it had no effect (Friling 2025). Sunflower-derived PS is soy-free and is the preferred option for anyone with soy sensitivity. No head-to-head comparison of the two was part of our 2026 review.

What is the FDA health claim for PS?

The FDA allows only a qualified claim that phosphatidylserine may reduce the risk of dementia or cognitive dysfunction in the elderly, with the disclaimer that 'FDA concludes that there is little scientific evidence supporting this claim' (FDA letter, 13 May 2003). The claim wording itself says that 'very limited and preliminary scientific research suggests' this.

What about the bovine brain source I see mentioned in older studies?

Original 1990s PS trials used bovine-cortex-derived PS. This source was discontinued globally after BSE (mad cow disease) concerns. All current commercial PS is plant- or marine-derived. The later plant- and marine-PS trials show memory benefits mainly in subgroups of older adults, so the older bovine results should not be assumed to transfer.

Does PS interact with blood thinners?

No clinical interaction between PS and anticoagulants was found in our 2026 PubMed review, and the main PS safety trial did not collect bleeding data. If you are on warfarin, aspirin, or other anticoagulants, consult your doctor before adding any supplement.

Top stacks containing Phosphatidylserine

Phosphatidylserine in Australia

Phosphatidylserine (PS) is listed in Australia's Therapeutic Goods (Permissible Ingredients) Determination as 'soy phosphatidylserine-enriched soy lecithin': a liquid at Schedule 1 item 4689 and a powder at item 4690, each with purpose code A (active ingredient). Both entries make soy phosphatidylserine a mandatory component and state that the maximum recommended daily dose of the medicine must not provide more than 300 mg of soy phosphatidylserine. The Therapeutic Goods Administration (TGA) says that if an ingredient isn't listed in the Determination, it can't be used in listed or assessed listed medicines; items 4689 and 4690 are the entries we found under the name 'phosphatidylserine' in Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940), checked 2026-10-08.

What the two phosphatidylserine entries require

Items 4689 (liquid) and 4690 (powder) of Schedule 1 carry the same two requirements: soy phosphatidylserine is a mandatory component of the ingredient, and 'the maximum recommended daily dose of the medicine must not provide more than 300 mg of soy phosphatidylserine.' The requirements column for each entry lists nothing else -- no sponsor-exclusivity clause of the kind attached to citicoline's entry (item 1428) and no label warning statement of the kind theanine's entry (item 4911) requires.

Products in Australia

TGA (AUST L)

Is phosphatidylserine a permitted ingredient in Australian listed medicines?

Yes, as soy phosphatidylserine-enriched soy lecithin. Schedule 1 of the Permissible Ingredients Determination lists it as a liquid (item 4689) and a powder (item 4690) for use as an active ingredient, with no more than 300 mg of soy phosphatidylserine in the medicine's maximum recommended daily dose (checked 2026-10-08).

Sources: Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, item 4689 (Soy phosphatidylserine-enriched soy lecithin liquid) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, item 4690 (Soy phosphatidylserine-enriched soy lecithin powder) · Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 (F2026L00707), as compiled 17 September 2026 (Compilation No. 1, F2026C00940) -- Schedule 1, items 4689 and 4690 (dose cap) · TGA -- Permissible ingredients determination (overview)

Regulatory note

Therapeutic goods available in Australia are regulated by the Therapeutic Goods Administration (TGA). AUST L–listed products carry pre-approved permitted indications; AUST R–registered products are higher-evidence. Imported products without TGA listing are not assessed by Australian regulators. This page is editorial, not promotional, and does not constitute medical advice. Always read the label and follow directions for use. Consult a qualified healthcare professional before starting any supplement.

Sources (6)expand